Andrew Johns, MD
Department of Genitourinary Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2017 | Indiana University School of Medicine, Indianapolis, Indiana, US, Human Medicine, Doctor of Medicine |
| 2013 | Indiana University, Bloomington, Indiana, US, Neuroscience, Bachelor of Science |
| 2013 | Indiana University, Indianapolis, Indiana, US, French, Spanish, Bachelor of Arts |
Postgraduate Training
| 2021-2024 | Fellow & Chief Fellow, Hematology and Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2017-2021 | Resident & Chief Resident, Internal Medicine, The Ohio State University, Columbus, Ohio |
Board Certifications
| 2023 | Advanced Cardiovascular Life Support Certification |
| 2020 | American Board of Internal Medicine, Internal Medicine Board Certification |
Experience & Service
Administrative Appointments/Responsibilities
Chief Fellow for Education, Department of Hematology and Medical Oncology Fellowship, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - 2024
Chief Resident for Education and Research, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, 2020 - 2021
Institutional Committee Activities
Member, Hematology and Medical Oncology fellowship program director interview committee, 2024 - 2024
Member, Hematology and Medical Oncology fellowship program candidate interview committee, 2023 - Present
Member, Housestaff Education Committee, 2017 - 2021
Alternate Representative, Housestaff Quality Forum, 2017 - 2019
Member, Pharmacy & Therapeutics Formulary Committee, 2017 - 2019
Member, Medical Student Activities Committee, 2015 - 2017
Member, Medical Student Technology Committee, 2015 - 2017
Student Chapter Vice President, Christian Medical and Dental Association, 2014 - 2015
Student Chapter Vice President, Christian Medical and Dental Association, 2013 - 2017
Honors & Awards
| 2024 | The Richard Theriault Humanitas Award, Hematology and Medical Oncology fellowship program, The University of Texas MD Anderson Cancer Center |
| 2023 | Conquer Cancer Foundation Merit Award, American Society of Clinical Oncology |
| 2023 | Nomination and Selection as Chief Fellow, Hematology and Medical Oncology fellowship program, University of Texas MD Anderson Cancer Center |
| 2019 | Dr. Michael R. Grever Award for the Outstanding Clinical Resident in Hematology & Oncology, Department of Internal Medicine, The Ohio State University Wexner Medical Center |
| 2019 | Resident Travel Award, American Geriatrics Society Annual Scientific Meeting |
| 2019 | Presidential Poster Session Selection, American Geriatrics Society Annual Scientific Meeting |
| 2019 | Nomination and Selection as Chief Resident, Department of Internal Medicine, The Ohio State University Wexner Medical Center |
| 2018 | Second Place Team, Doctor’s Dilemma Competition, American College of Physicians Ohio/Air Force Chapter Scientific Meeting |
| 2018 | Third Place, Clinical Vignette Poster Presentation, American College of Physicians Ohio/Air Force Chapter Scientific Meeting |
| 2018 | “Top Ten Provider Comments of the Week”, The Ohio State University Wexner Medical Center |
| 2017 | Dr. Franklin Bryan Award for Excellence in Patient Care, Indiana University School of Medicine |
| 2015 | Professor Joel A. Vilensky Technology Grant, Indiana University School of Medicine |
| 2013 | Provost’s Award for Undergraduate Research and Creative Activity, Indiana University |
| 2012 | Phi Beta Kappa, Indiana University |
| 2012 | Grace P. Young Award, Department of French and Italian, Indiana University |
| 2009 | Herman B Wells Scholar, Indiana University |
Selected Publications
Peer-Reviewed Articles
- Wang E, Rupe ES, Mukhida SS, Johns AC, Campbell MT, Shah AY, Zurita AJ, Gao J, Goswami S, Jonasch E, Msaouel P, Tannir NM, Hahn AW. Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell Carcinoma. Eur Urol Focus None(None):None, 2024. PMID: 39307587.
- Johns AC, Campbell MT, Gao M, Hahn AW, Lim Z, Wang E, Gao J, Shah AY, Msaouel P, Tannir NM. Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma. Oncologist None(None):None, 2024. PMID: 38478923.
- Johns AC, Yang M, Wei L, Grogan M, Spakowicz D, Patel SH, Li M, Husain M, Kendra KL, Otterson GA, Rosko AE, Andersen BL, Carbone DP, Owen DH, Presley CJ. Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer. Oncologist 28(8):e625-e632, 2023. PMID: 37085156.
- Johns AC, Yang M, Wei L, Grogan M, Patel SH, Li M, Husain M, Kendra KL, Otterson GA, Burkart JT, Spakowicz D, Hoyd R, Owen DH, Presley CJ. Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapy. Cancer Immunol Immunother 72(7):2005-2013, 2023. PMID: 36738310.
- Guo Y, Wei L, Patel SH, Lopez G, Grogan M, Li M, Haddad T, Johns A, Ganesan LP, Yang Y, Spakowicz DJ, Shields PG, He K, Bertino EM, Otterson GA, Carbone DP, Presley C, Kulp SK, Mace TA, Coss CC, Phelps MA, Owen DH. Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy. Clin Lung Cancer 23(4):345-355, 2022. PMID: 35131184.
- Haddad TC, Zhao S, Li M, Patel SH, Johns A, Grogan M, Lopez G, Miah A, Wei L, Tinoco G, Riesenberg B, Li Z, Meara A, Bertino EM, Kendra K, Otterson G, Presley CJ, Owen DH. Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival. Cancer Immunol Immunother 71(5):1157-1165, 2022. PMID: 34618180.
- Nashed A, Zhang S, Chiang CW, Zitu M, Otterson GA, Presley CJ, Kendra K, Patel SH, Johns A, Li M, Grogan M, Lopez G, Owen DH, Li L. Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events. Cancer Immunol Immunother 70(10):2761-2769, 2021. PMID: 33625533.
- Johns AC, Wei L, Grogan M, Hoyd R, Bridges JFP, Patel SH, Li M, Husain M, Kendra KL, Otterson GA, Burkart JT, Rosko AE, Andersen BL, Carbone DP, Owen DH, Spakowicz DJ, Presley CJ. Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer. J Geriatr Oncol 12(5):813-819, 2021. PMID: 33627226.
- Qin A, Zhao S, Miah A, Wei L, Patel S, Johns A, Grogan M, Bertino EM, He K, Shields PG, Kalemkerian GP, Gadgeel SM, Ramnath N, Schneider BJ, Hassan KA, Szerlip N, Chopra Z, Journey S, Waninger J, Spakowicz D, Carbone DP, Presley CJ, Otterson GA, Green MD, Owen DH. Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. J Natl Compr Canc Netw 19(8):915-921, 2021. PMID: 33878726.
- Li M, Spakowicz D, Zhao S, Patel SH, Johns A, Grogan M, Miah A, Husain M, He K, Bertino EM, Shields PG, Wei L, Carbone DP, Otterson GA, Presley CJ, Owen DH. Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer. Cancer Immunol Immunother 69(11):2403-2408, 2020. PMID: 32728772.
- Spakowicz D, Hoyd R, Muniak M, Husain M, Bassett JS, Wang L, Tinoco G, Patel SH, Burkart J, Miah A, Li M, Johns A, Grogan M, Carbone DP, Verschraegen CF, Kendra KL, Otterson GA, Li L, Presley CJ, Owen DH. Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications. BMC Cancer 20(1):383, 2020. PMID: 32375706.
Other Articles
- Jackson JC, Sanchez D, Johns AC, Campbell MT, Aydin AM, Gokden N, Maraboyina S, Muesse JL, Ward JF, Pisters LL, Zacharias NM, Guo CC, Tu SM Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable Cancer. J Clin Med 13(12):None, 2024. PMID: 38929965.
- Miah A, Tinoco G, Zhao S, Wei L, Johns A, Patel S, Li M, Grogan M, Lopez G, Husain M, Hoyd R, Mumtaz K, Meara A, Bertino EM, Kendra K, Spakowicz D, Otterson GA, Presley CJ, Owen DH Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival. J Cancer Res Clin Oncol 149(5):2235-2242, 2023. PMID: 36070148.
- Johns AC, Campbell MT Toxicities From Antibody-Drug Conjugates. Cancer J 28(6):469-478, 2022. PMID: 36383910.
- Johns AC, Sorenson C, Rogers A, Agne JL, D'Souza DM, Das JK, Issa M, Perna G, Williams TM, Meara A, Kitchin T, Haglund KE, Owen DH Clinical Course of Hypertrophic Pulmonary Osteoarthropathy in a Patient Receiving Immune Checkpoint Inhibitor Therapy. Clin Lung Cancer 21(4):e243-e245, 2020. PMID: 32067849.
- Dempsey JL, Johns A, Rosko AE, Lazarus HM The pharmacologic management of multiple myeloma in older adults. Expert Opin Pharmacother 20(7):887-902, 2019. PMID: 30785310.